Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates


Follow the latest updates of the outbreak on our timeline.


The US Food and Drug Administration (FDA) has granted an emergency use authorisation (EUA) to Fosun Pharma for its Covid-19 RT-PCR detection kit.

The kit enables the qualitative detection of novel coronavirus RNA by targeting its specific ORF1ab, N and E genes. It supports fast automatic nucleic acid extraction instrument and extraction reagents and can complete the detection of 96 samples in less than two hours.

Fosun Pharma noted that automated testing can reduce the risk of operator infection and the probability of cross-contamination in clinical laboratories. Moreover, it will also help to improve detection efficiency.

Developed by the company’s wholly owned subsidiary Fosun Long March, the Covid-19 detection kit secured CE certification from the EU.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It also received the medical device registration certificate issued by the China National Medical Products Administration (NMPA).

Last month, Fosun Pharma initiated a strategic development and commercialisation collaboration with BioNTech for the prevention of Covid-19 infections.

Both companies will work together on the development of Covid-19 vaccines based on BioNTech’s mRNA technology platform in China.

Additionally, they will conduct clinical trials in China, using Fosun Pharma’s clinical development, as well as regulatory and commercial capabilities in the country.

Founded in 1994, Fosun Pharma specialises in PCR hepatitis B virus diagnostic reagents. Currently, the company has a comprehensive medical diagnosis product line with a nationwide marketing network in China.

The product line covers biochemical diagnosis, immune diagnosis, molecular diagnosis and microbial diagnosis, POCT and mass spectrometry, and third-party detection service products.